Scarica l'app Stockscreener
71.83
0.32%
0.23
Dopo l'orario di chiusura:
71.89
0.06
+0.08%
Precedente Chiudi:
$71.60
Aprire:
$71.59
Volume 24 ore:
1.59M
Relative Volume:
0.32
Capitalizzazione di mercato:
$10.82B
Reddito:
$10.73M
Utile/perdita netta:
$-455.74M
Rapporto P/E:
-20.19
EPS:
-3.5569
Flusso di cassa netto:
$-502.70M
1 W Prestazione:
+0.28%
1M Prestazione:
+1.43%
6M Prestazione:
+123.49%
1 anno Prestazione:
+112.77%
Intervallo 1D:
$71.52
$71.88
Intervallo di 1 settimana:
$71.18
$71.88
Portata 52W:
$21.51
$72.05
Avidity Biosciences Inc Stock (RNA) Company Profile
Nome
Avidity Biosciences Inc
Settore
Industria
Telefono
858-401-7900
Indirizzo
3020 CALLAN ROAD, SAN DIEGO, CA
Confronta RNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
71.83 | 10.79B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-17 | Iniziato | Roth Capital | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2025-06-24 | Iniziato | Bernstein | Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-06-11 | Iniziato | Raymond James | Strong Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-03-12 | Iniziato | BMO Capital Markets | Outperform |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-11-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-09-24 | Iniziato | Goldman | Buy |
| 2024-08-28 | Iniziato | Barclays | Overweight |
| 2024-05-03 | Iniziato | BofA Securities | Buy |
| 2024-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-05-22 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-03-31 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-07-20 | Iniziato | Chardan Capital Markets | Buy |
| 2022-07-12 | Iniziato | Raymond James | Strong Buy |
| 2021-09-07 | Iniziato | Evercore ISI | Outperform |
| 2021-06-17 | Iniziato | Needham | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | Cowen | Outperform |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-07-07 | Iniziato | SVB Leerink | Outperform |
| 2020-07-07 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Avidity Biosciences Inc Borsa (RNA) Ultime notizie
Frazier Life Sciences Management L.P. Has $17.75 Million Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences (NASDAQ:RNA) Reaches New 52-Week HighWhat's Next? - MarketBeat
EcoR1 Capital LLC Sells 57,576 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity - MSN
Avidity Biosciences stock hits all-time high at 71.81 USD - Investing.com
Aug Closing: Is Avidity Biosciences Inc stock vulnerable to regulatory risksTrade Performance Summary & Growth-Oriented Investment Plans - moha.gov.vn
Avoiding Lag: Real-Time Signals in (RNA) Movement - news.stocktradersdaily.com
Assessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price Surge - Yahoo Finance
Dyne stock upgraded at Oppenheimer (DYN:NASDAQ) - Seeking Alpha
Dyne Therapeutics' Biggest Catalyst is Avidity Biosciences' DM1 Readout in H2 2026, Oppenheimer Says - marketscreener.com
Norges Bank Makes New Investment in Avidity Biosciences, Inc. $RNA - MarketBeat
Franklin Resources Inc. Sells 29,465 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
JPMorgan Chase & Co. Buys 139,473 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences stock hits all-time high at 71.78 USD By Investing.com - Investing.com South Africa
Avidity Biosciences stock hits all-time high at 71.78 USD - Investing.com
Why Avidity Biosciences Inc. stock could benefit from AI revolution2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - Newser
Avidity Biosciences, Inc. (RNA): A Bull Case Theory - Finviz
Schroder Investment Management Group Raises Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
How Avidity Biosciences Inc. stock reacts to Fed rate cutsEarnings Overview Summary & AI Enhanced Trade Execution Alerts - Newser
Avidity Biosciences, Inc. $RNA Shares Sold by Steward Partners Investment Advisory LLC - MarketBeat
Avidity Biosciences, Inc. $RNA Shares Sold by Prudential Financial Inc. - MarketBeat
Will Avidity Biosciences Inc. stock outperform Dow Jones indexMarket Growth Report & Detailed Earnings Play Alerts - Newser
Creative Planning Grows Stock Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44 (PR Newswire) - Aktiellt
Discipline and Rules-Based Execution in RNA Response - news.stocktradersdaily.com
Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026 (PR Newswire) - Aktiellt
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society (PR Newswire) - Aktiellt
Update Recap: Can Avidity Biosciences Inc. stock sustain free cash flow growth2025 Risk Factors & Reliable Entry Point Alerts - BỘ NỘI VỤ
What analysts say about Avidity Biosciences Inc stockSwing Trading Watchlist & Investment Timing Techniques - earlytimes.in
SG Americas Securities LLC Raises Holdings in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights (PR Newswire) - Aktiellt
Avidity Biosciences, Inc. $RNA Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Dyne Therapeutics Stock Soars After Rival Avidity Biosciences Gets Acquired By Novartis - MSN
Avidity Played Hardball to Land Favorable Terms in $12B Novartis Deal - BioSpace
Avidity Biosciences stock hits all-time high at 71.1 USD By Investing.com - Investing.com Nigeria
Avidity Biosciences stock hits all-time high at 71.1 USD - Investing.com
Ensign Peak Advisors Inc Purchases 200,836 Shares of Avidity Biosciences, Inc. $RNA - MarketBeat
Halper Sadeh LLC Encourages WTRG, RNA, TCBX Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Artisan Partners Limited Partnership Has $25.05 Million Stake in Avidity Biosciences, Inc. $RNA - MarketBeat
Avidity Biosciences Inc. (RNA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Avidity Biosciences Inc Stock Analysis and ForecastStochastic Oscillator Alerts & Rapid Capital Trading - earlytimes.in
How Avidity Biosciences Inc. stock trades during market volatilityMarket Rally & Reliable Breakout Forecasts - newser.com
How Avidity Biosciences Inc. stock performs after earnings2025 Market Trends & Daily Growth Stock Investment Tips - newser.com
Key facts: Novartis to Acquire Avidity for $12B; Raises Sales Guidance - TradingView
Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 - BioSpace
Will Avidity Biosciences Inc. stock deliver long term returns2025 Market Outlook & Long-Term Safe Return Strategies - newser.com
Price action breakdown for Avidity Biosciences Inc.Quarterly Profit Review & Expert Approved Momentum Ideas - newser.com
Is Avidity Biosciences Inc. showing signs of accumulationBreakout Watch & Low Drawdown Momentum Ideas - newser.com
Using AI based signals to follow Avidity Biosciences Inc.Quarterly Portfolio Review & Technical Analysis for Trade Confirmation - newser.com
Will Avidity Biosciences Inc. stock attract more institutional investorsIndex Update & Community Shared Stock Ideas - newser.com
What Wall Street predicts for Avidity Biosciences Inc. stock priceRate Cut & Low Drawdown Trading Techniques - newser.com
Avidity Biosciences Inc Azioni (RNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Avidity Biosciences Inc Azioni (RNA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hughes Steven George | Chief Medical Officer |
Oct 22 '25 |
Sale |
47.54 |
2,209 |
105,015 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Option Exercise |
22.34 |
20,000 |
446,800 |
117,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Oct 15 '25 |
Sale |
50.15 |
20,000 |
1,003,058 |
97,130 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Option Exercise |
9.05 |
6,562 |
59,386 |
61,562 |
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):